Oncoinvent's Radspherin® Study Reaches Halfway Recruitment Mark for Ovarian Cancer Trial

Oncoinvent Achieves 50% Recruitment Milestone in Phase 2 Study of Radspherin®

Oncoinvent ASA, a company focused on developing innovative cancer therapies, recently announced the achievement of a significant milestone in its Phase 2 clinical trial of Radspherin®, a radiopharmaceutical aimed at treating ovarian cancer. The trial, which assesses the safety and efficacy of Radspherin® for patients suffering from peritoneal metastases following surgical removal of tumors, has now successfully enrolled 54 patients, marking the halfway point in the recruitment phase.

Accelerated Recruitment in 2026

The momentum for patient recruitment has notably increased this year. In the initial quarter of 2026, 11 patients were enrolled, sharply rising to 17 patients in the second quarter alone. This surge surpasses the total number of patients enrolled throughout the entire year of 2025, showcasing a significant acceleration in interest and participation in the trial.

To facilitate this remarkable progress, four new recruitment sites have recently opened, bringing the total to ten active hospitals located across several countries including the United States, Spain, Norway, Belgium, the United Kingdom, and Italy. With further site activations in the pipeline, Oncoinvent aims to continue this trajectory to enhance research outcomes and fulfill trial requirements in the coming months.

According to Oystein Soug, CEO of Oncoinvent, reaching this 50% recruitment milestone is not only a vital aspect of the trial but also illustrates the dedicated efforts from investigators and participating sites. "We are thrilled by the visible momentum in recruitment that resulted from our committed strategies," Soug stated. He also expressed optimism regarding Radspherin's ability to provide new hope for patients with ovarian cancer, a demographic often left with limited treatment options post-surgery.

The Trial's Objective

The primary goal of this Phase 2 trial, registered under ClinicalTrials.gov NCT06504147, is to evaluate the progression-free survival rates of patients treated with Radspherin® after complete surgical resection compared to standard care involving chemotherapy and surgery alone. This randomized controlled study seeks to provide conclusive data about Radspherin®’s efficacy while simultaneously assuring patient safety.

Previous studies, including Phase 1 and Phase 1/2a trials, have indicated that Radspherin® is well tolerated by patients, exhibiting no dose-limiting toxicity at the recommended dose of 7MBq. Furthermore, preliminary efficacy signals have shown promise, further boosting confidence in the treatment's potential. The results from these earlier trials have been published in reputable peer-reviewed journals, strengthening the evidence supporting Radspherin® as a potential game-changer in ovarian cancer treatment.

Future Prospects

As Oncoinvent continues to advance the deployment of Radspherin®, the hope is that this therapy can significantly improve the quality of life and outcomes for those facing the challenges of ovarian cancer. Investigators are eagerly awaiting further results from ongoing trials to determine the full potential of this targeted treatment and its impact on the landscape of cancer therapies.

With ongoing recruitment and clinical progress, Oncoinvent is on a promising path toward potentially introducing a breakthrough treatment that may change the lives of many patients worldwide suffering from this challenging condition.